# Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma

> **NCT07068568** · — · COMPLETED · sponsor: **Federico II University** · enrollment: 12 (actual)

## Conditions studied

- Basal Cell Cancer
- Eyelid Tumor
- Basal Cell Carcinoma (BCC)
- Basal Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Sonidegib

## Key facts

- **NCT ID:** NCT07068568
- **Lead sponsor:** Federico II University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-11
- **Primary completion:** 2023-12-20
- **Final completion:** 2024-03-20
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07068568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07068568, "Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07068568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*